MY171723A - Pharmaceutical compositions of tenecteplase - Google Patents

Pharmaceutical compositions of tenecteplase

Info

Publication number
MY171723A
MY171723A MYPI2013002136A MYPI2013002136A MY171723A MY 171723 A MY171723 A MY 171723A MY PI2013002136 A MYPI2013002136 A MY PI2013002136A MY PI2013002136 A MYPI2013002136 A MY PI2013002136A MY 171723 A MY171723 A MY 171723A
Authority
MY
Malaysia
Prior art keywords
tenecteplase
pharmaceutical compositions
compositions
tnk
treatment
Prior art date
Application number
MYPI2013002136A
Other languages
English (en)
Inventor
Maheshwari Kumar Mishra
Pritiranjan Bhandari
Sanjay Singh
Original Assignee
Gennova Biopharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46313261&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY171723(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gennova Biopharmaceuticals Ltd filed Critical Gennova Biopharmaceuticals Ltd
Publication of MY171723A publication Critical patent/MY171723A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46Hydrolases (3)
    • A61K38/48Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482Serine endopeptidases (3.4.21)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y304/00Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21Serine endopeptidases (3.4.21)
    • C12Y304/21068Tissue plasminogen activator (3.4.21.68), i.e. tPA

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MYPI2013002136A 2010-12-23 2011-12-16 Pharmaceutical compositions of tenecteplase MY171723A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN3516MU2010 2010-12-23

Publications (1)

Publication Number Publication Date
MY171723A true MY171723A (en) 2019-10-24

Family

ID=46313261

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2013002136A MY171723A (en) 2010-12-23 2011-12-16 Pharmaceutical compositions of tenecteplase

Country Status (17)

Country Link
US (2) US20130323227A1 (enExample)
EP (1) EP2654770B1 (enExample)
JP (1) JP6375112B2 (enExample)
CN (1) CN103391785A (enExample)
AU (1) AU2011346515B2 (enExample)
BR (1) BR112013015914B1 (enExample)
CO (1) CO6721059A2 (enExample)
DK (1) DK2654770T3 (enExample)
EA (1) EA026017B1 (enExample)
ES (1) ES2687850T3 (enExample)
LT (1) LT2654770T (enExample)
MX (1) MX356199B (enExample)
MY (1) MY171723A (enExample)
NZ (1) NZ611706A (enExample)
PL (1) PL2654770T3 (enExample)
PT (1) PT2654770T (enExample)
WO (1) WO2012085933A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3209767B1 (en) * 2014-10-21 2020-08-05 Gennova Biopharmaceuticals Ltd. A novel purification process for isolation and commercial production of recombinant tnk-tpa (tenecteplase)
CN110913890A (zh) * 2017-05-16 2020-03-24 国家医疗保健研究所 用于治疗急性缺血性中风的方法和药物组合物
US20210214702A1 (en) * 2018-06-01 2021-07-15 Gennova Biopharmaceuticals Limited Process for production of recombinant tnk-tpa by packed-bed perfusion system
CN114984197A (zh) * 2022-07-01 2022-09-02 江苏丰华生物制药有限公司 替奈普酶在制备用于治疗急性缺血性卒中的药物组合物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10230752A1 (de) * 2002-07-09 2004-01-22 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkompositionen auf der Basis von Magnesiumsalzen und Fibrinolytika
US20070014779A1 (en) * 2002-11-14 2007-01-18 Genentech, Inc. Plasminogen activator variant formulations
US20070166299A1 (en) * 2005-03-02 2007-07-19 The Regents Of The University Of California Treatment for embolic stroke
WO2006094120A2 (en) * 2005-03-02 2006-09-08 The Regents Of The University Of California Treatment for embolic stroke
NZ574767A (en) * 2006-08-29 2012-02-24 Genentech Inc Use of tenecteplase for treating acute ischemic stroke
US8916148B2 (en) * 2006-11-07 2014-12-23 Genentech, Inc. Tissue plasminogen activator variant uses
EP2014760A1 (en) * 2007-06-13 2009-01-14 CMC Biopharmaceuticals A/S A method for producing a biopolymer (e.g. polypeptide) in a continuous fermentation process

Also Published As

Publication number Publication date
EP2654770B1 (en) 2018-07-11
US20130323227A1 (en) 2013-12-05
ES2687850T3 (es) 2018-10-29
US9943575B2 (en) 2018-04-17
AU2011346515A1 (en) 2013-07-04
AU2011346515B2 (en) 2017-01-19
US20160310580A1 (en) 2016-10-27
BR112013015914A2 (pt) 2016-10-11
DK2654770T3 (en) 2018-10-29
NZ611706A (en) 2015-04-24
EA201300746A1 (ru) 2013-11-29
BR112013015914B1 (pt) 2021-06-08
WO2012085933A1 (en) 2012-06-28
PL2654770T3 (pl) 2018-12-31
EA026017B1 (ru) 2017-02-28
CO6721059A2 (es) 2013-07-31
MX356199B (es) 2018-05-18
LT2654770T (lt) 2018-09-10
JP2014502608A (ja) 2014-02-03
PT2654770T (pt) 2018-10-19
EP2654770A4 (en) 2014-05-21
JP6375112B2 (ja) 2018-08-15
EP2654770A1 (en) 2013-10-30
MX2013007381A (es) 2013-08-29
CN103391785A (zh) 2013-11-13

Similar Documents

Publication Publication Date Title
EP2877159B8 (en) Efflux inhibitor compositions and methods of treatment using the same
EP4620520A3 (en) Methods and compositions relating to chondrisomes
AU333421S (en) Showerhead
EA201291031A1 (ru) Способ лечения ожирения с применением антиоксидантных модуляторов воспаления
UA109123C2 (uk) Пробіотична композиція для застосування в лікуванні запалення кишечнику
IN2014CN04251A (enExample)
BR112015011756A2 (pt) inibidores da glutamase e métodos de uso
AR125920A2 (es) Composiciones que comprenden vortioxetina y donepezil
IN2014DN09412A (enExample)
WO2012073047A3 (en) Compositions and methods
GB2497453B (en) Pharmaceutical composition and methods of treating and preventing the diseases caused by HIV or associated with HIV
MX359181B (es) Hidrolizado de colágeno y uso del mismo.
PH12015501099A1 (en) Synbiotic composition and use thereof
MY171723A (en) Pharmaceutical compositions of tenecteplase
UA112760C2 (uk) Теобромін у комбінації з гвайфенезином для лікування кашлю
ZA201503604B (en) Fibrinolytic compositions comprising bromelain and nattokinase for the prevention and treatment of phlebothrombotic states
PH12015501147A1 (en) Synbiotic composition and use thereof
UA73592U (ru) Применение экстракта травы герани крупнокорневищной как средства с противовоспалительной и обезболивающей активностью
UA61166U (en) Use of glucosamine hydrochloride as antiamnestic and antihypoxic agent
UA96649C2 (ru) Применение глюкозамина гидрохлорида как средства фригопротекторной действия
AU337239S (en) Tri maintenance shaft base
UA41660U (en) Use of jacton and mexidol as actoprotector
UA102047C2 (uk) ГЕПАТОЗАХИСНА ТА АНТИОКСИДАНТНА АКТИВНІСТЬ ШТАМУ РЕЛІКТОВИХ БАКТЕРІЙ BACILLUS sp. F
AU2010904022A0 (en) Nitriding of Niobium Steel and Product made thereby